# Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia

Study · id `cardio:ct-nct02928094` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02928094](<https://clinicaltrials.gov/study/NCT02928094>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02928094

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.

## Technical summary

Registry record NCT02928094. Randomized; triple masking; primary purpose treatment. Start 2023-01-01 (anticipated); primary completion 2024-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 160 participants (planned count; ClinicalTrials.gov record NCT02928094, source copy `cardio:ctgov-nct02928094-2022-07-19`, retrieved 2026-10-31)
- Planned start: 2023-01-01 (anticipated) (ClinicalTrials.gov record NCT02928094, source copy `cardio:ctgov-nct02928094-2022-07-19`, retrieved 2026-10-31)
- Primary completion: 2024-03-01 (anticipated) (ClinicalTrials.gov record NCT02928094, source copy `cardio:ctgov-nct02928094-2022-07-19`, retrieved 2026-10-31)
- Completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT02928094, source copy `cardio:ctgov-nct02928094-2022-07-19`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02928094-2022-07-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia
- Acronym: AFFIRM
- Condition: Angina, Stable
- Intervention (Biological): Ad5FGF-4
- Intervention (Biological): Placebo
- Lead sponsor: Angionetics Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Huapont Life Sciences
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Angina pectoris (`cardio:angina-pectoris`)
- Registry condition terms include this condition: Stable angina (`cardio:stable-angina`)

## Provenance

Content hash: 59c4e88acb435ed6c7ef2a9819cfd40cb5b3f62b2a0a2b2feb6e1b2f272eb212
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
